Literature DB >> 30031712

Inherited platelet functional disorders: General principles and practical aspects of management.

Adrienne Lee1, Man-Chiu Poon2.   

Abstract

Platelets are a critical component for effecting hemostasis and wound healing. Disorders affecting any platelet pathway mediating adhesion, activation, aggregation and procoagulant surface exposure can result in a bleeding diathesis. Specific diagnosis even with advanced techniques which are unavailable to most centers is often difficult. Inherited platelet function disorders therefore represent a heterogeneous and complex collection of disorders with a spectrum of bleeding severity, from relatively mild (and easily missed or misdiagnosed) to severe bleeding phenotype with salient diagnostic features. We advocate the use of bleeding assessment tools to help identification of patients and more importantly for assessment of individual patient bleeding phenotype to guide management decisions for treating and preventing bleeding. The complex management of these patients is best coordinated in a multidisciplinary comprehensive care clinic setting expert in managing bleeding disorders and associated complications, with particular attention to the physical and psychosocial health of patients and their families. Depending on the bleeding phenotype, the location and severity of bleeding, and the nature of an invasive procedure, available treatment modalities range from conservative measures using local pressure, topical thrombin, fibrin sealant, antifibrinolytics etc. to the use of systemic haemostatics such as desmopressin (DDAVP), platelets and recombinant human activated factor VII (rFVIIa). This review will provide opinions on the practical aspects and general management of inherited platelet function disorders, with discussion on the mechanism of action, and the pros and cons of various hemostatic agents. Finally, the prospect of curative treatment for patients with severe bleeding phenotype refractory to available treatments and with poor quality of life will be briefly discussed.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antifibrinolytics; Bernard Soulier syndrome; Diagnosis; Glanzmann’s Thrombasthenia; Inherited platelet function disorders (IPFD); Management; Platelet transfusion; Recombinant human activated factor VII (rFVIIa); desmopressin/DDAVP

Mesh:

Substances:

Year:  2018        PMID: 30031712     DOI: 10.1016/j.transci.2018.07.010

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  4 in total

1.  Pregnancy and Delivery Management With Recombinant Factor VIIa in a Glanzmann Thrombasthenia Patient: A Case Report.

Authors:  Leonardo Enciso; Rafael L Aragón-Mendoza; Laura A León; Carrie G Torres-Torres
Journal:  Cureus       Date:  2022-02-24

2.  Disease Burden in Patients with Glanzmann's Thrombasthenia: Perspectives from the Glanzmann's Thrombasthenia Patient/Caregiver Questionnaire.

Authors:  Alexander Duncan; Angela Kellum; Skye Peltier; David L Cooper; Hossam Saad
Journal:  J Blood Med       Date:  2020-09-11

Review 3.  Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia.

Authors:  José María Bastida; José Ramón Gonzalez-Porras; José Rivera; María Luisa Lozano
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 4.  Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.

Authors:  Natalie Mathews; Georges-Etienne Rivard; Arnaud Bonnefoy
Journal:  J Blood Med       Date:  2021-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.